Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00225147 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema
Angioneurotic Edema

Interventions

DRUG: Recombinant Human C1 Inhibitor
DRUG: placebo

Sponsor

Pharming Technologies B.V.